UPL Limited has completed critical conditions precedent for its proposed Composite Scheme of Arrangement, including the completion of Swap and Employee Stock Option (ESOP) Swap transactions on July 31, 2026. The agrochemical major also confirmed it received approval from the Competition Commission of India (CCI) on June 3, 2026. These developments clear significant regulatory hurdles, allowing UPL to proceed with filing the scheme before the National Company Law Tribunal (NCLT), subject to other remaining approvals.

Completion of Swap Transactions

The Swap Transaction and ESOP Swap Transaction were undertaken to consolidate the India Crop Protection Business held in UPL Sustainable Agri Solutions Limited (UPL SAS) and the Global Crop Protection Business held in UPL Crop Protection Holdings Limited (UPL Cayman 1) under a single entity. This restructuring aims to create a focused, pure-play crop protection platform.

Pursuant to the transactions:

• All holders of employee stock options in UPL Corporation Ltd., Cayman (UPL Cayman 2) under the Cayman 2 ESOP Scheme have been issued new stock options in UPL Cayman 1 under the UCPL LTI Plan 2026.
• UPL Cayman 2 has become a wholly owned subsidiary of UPL Cayman 1.

The company stated that these internal restructuring steps do not result in any material change in the consolidated assets, liabilities, revenues, profitability, or net worth of the Group. No benefit accrues to the promoter or promoter group from these transactions.

Changes in Shareholding Pattern

The completion of the swaps has altered the shareholding structure of UPL Cayman 1 and UPL Cayman 2. Previously, UPL Corporation Limited, Mauritius held 100% of UPL Cayman 1. Post-transaction, the ownership is diversified among the Mauritius entity, the Upswing Trust, and employee option holders.

Note: Percentages are on a fully diluted basis, assuming all employee stock options are exercised. UPL Cayman 2 is now wholly owned by UPL Cayman 1.

Regulatory Milestones and Next Steps

Earlier, on July 29, 2026, UPL received 'no adverse observations' from BSE Limited and 'No Objection' from the National Stock Exchange of India Limited (NSE). These observation letters are valid for six months, requiring the company to submit the scheme to the NCLT by January 29, 2027.

The Securities and Exchange Board of India (SEBI) has mandated that UPL disclose ongoing adjudication proceedings, ensure financials used for valuation are not older than six months, and provide details of Revenue, Profit After Tax (PAT), and EBITDA for all involved entities for the last three years. The listing of the resulting entity, UPL Global Sustainable Agri Solutions Limited, remains subject to SEBI approval and exchange discretion, including the freezing of allotted shares until trading permission is granted.

UPL Limited has moved to streamline its portfolio by divesting its entire stake in Bioplanta Nutricao Vegetal Industria e Comercio S.A., a joint venture company, for a nominal consideration of USD 20. The sale was executed by UPL do Brasil Industria e Comercio de Insumos Agropecuarios S.A., a subsidiary of UPL Limited, which secured all necessary regulatory approvals on July 29, 2026. The transaction is expected to be completed on or before July 31, 2026.

The divestment targets an associate company that reported negative financials in FY25. Under IND AS, Bioplanta does not contribute to UPL's consolidated revenue from operations. The move allows the group to exit an entity with a negative net worth, aligning with management's stated focus on profitable growth. The buyers are Marino Jose Franz and Miguel Vaz Ribeiro, Brazilian citizens and businessmen who do not belong to the promoter group or related parties of UPL Limited.

Financial Profile of Bioplanta

Bioplanta is engaged in the manufacture, sale, importation, exportation, and tolling of fertilizers, agrochemicals, adjuvants, and agriculture inputs. Despite generating revenue, the entity operated at a loss during the last financial year. The financial details for FY25 are outlined below:

The negative net worth of USD 8.20 million and a loss of USD 3.10 million highlight the operational challenges faced by the joint venture. By selling the stake for USD 20, UPL effectively sheds this liability without significant cash outflow or complex restructuring costs.

Regulatory Compliance

UPL Limited disclosed the transaction under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/CFD-Pod1/P/CIR//2023/123 dated July 13, 2023. The intimation was submitted to BSE Limited and National Stock Exchange of India Ltd on July 29, 2026. The company confirmed that the transaction does not fall within the ambit of related party transactions and is not part of any Scheme of Arrangement under Regulation 37A of the LODR Regulations.

What the Numbers Show

The divestment reflects a strategic cleanup of the balance sheet rather than a revenue-generating event. While Bioplanta generated USD 7.10 million in revenue in FY25, its inability to convert this into profit—evidenced by a USD 3.10 million loss and negative net worth—made it a drag on the group's overall financial health. Removing such entities simplifies the corporate structure and eliminates ongoing monitoring costs associated with loss-making associates. For investors, the significance lies in the removal of a negative net-worth asset, albeit at a nominal value, signaling a continued focus on core profitability drivers.